Aduro Biotech (NASDAQ:ADRO), A rise of 559,364 shares or 14.2% was seen in the short interest of Aduro Biotech, Inc.. Even as the interest increased from 3,947,978 shares on May 31,2016 to 4,507,342 shares on June 15,2016, the days to cover came in at 13. The updated interest stood at 19.3% of the stocks floats. The stock has seen an average daily volume of 358,908 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.
Aduro Biotech (NASDAQ:ADRO): The stock opened at $10.27 on Friday but the bulls could not build on the opening and the stock topped out at $10.73 for the day. The stock traded down to $10.02 during the day, due to lack of any buying support eventually closed down at $10.10 with a loss of -7.59% for the day. The stock had closed at $10.93 on the previous day. The total traded volume was 3,652,946 shares.
The company shares have dropped -65.86% from its 1 Year high price. On Dec 16, 2015, the shares registered one year high at $34.95 and the one year low was seen on May 16, 2016. The 50-Day Moving Average price is $11.27 and the 200 Day Moving Average price is recorded at $16.13.
Aduro Biotech (NASDAQ:ADRO) has tumbled 10.38% during the past week and has dropped 13.75% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 8.89%. Aduro Biotech (NASDAQ:ADRO) has underperformed the index by 11.14% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Aduro BioTech Inc is a United States-based clinical-stage immunotherapy company. The Company has developed or acquired technology platforms designed to activate potent and lasting immune responses against cancer: live, attenuated Listeria, GVAX and cyclic dinucleotides (CDNs). Aduros lead program is an immunotherapy regimen combining Listeria-based CRS-207 and GVAX Pancreas in patients with metastatic pancreatic cancer who have failed at least one therapy. Its pipeline includes CRS-207, ADU-623, ADU-214, ADU-741, CDN and STINGVAX. CRS-207 is based on Aduros Listeria platform. ADU-623 is Aduros first clinical bivalent Listeria-based immunotherapy. ADU-214 is a bivalent Listeria-based immunotherapy that targets both mesothelin and an EGFR mutation. CDNs are small molecules that signal through STING and induce a potent immune response. STINGVAX is the combination of CDNs and GVAX.